U.S. markets closed
  • S&P Futures

    4,306.25
    -1.50 (-0.03%)
     
  • Dow Futures

    34,116.00
    -2.00 (-0.01%)
     
  • Nasdaq Futures

    13,646.50
    -11.75 (-0.09%)
     
  • Russell 2000 Futures

    2,023.30
    0.00 (0.00%)
     
  • Crude Oil

    86.62
    +0.09 (+0.10%)
     
  • Gold

    1,789.20
    -0.50 (-0.03%)
     
  • Silver

    20.05
    -0.04 (-0.20%)
     
  • EUR/USD

    1.0171
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    2.8240
    +0.0330 (+1.18%)
     
  • Vix

    19.69
    -0.26 (-1.30%)
     
  • GBP/USD

    1.2105
    +0.0011 (+0.09%)
     
  • USD/JPY

    134.1900
    -0.0250 (-0.02%)
     
  • BTC-USD

    23,998.45
    -198.85 (-0.82%)
     
  • CMC Crypto 200

    570.84
    -1.08 (-0.19%)
     
  • FTSE 100

    7,536.06
    +26.91 (+0.36%)
     
  • Nikkei 225

    29,091.19
    +222.28 (+0.77%)
     

Regencell Bioscience's COVID-19 Candidate Shows Encouraging Action On Mild To Moderate Symptoms

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the results from the EARTH efficacy trial of its COVID-19 candidate.

  • RGC-COV19 (Regencell Bioscience (RGCA-CV01) liquid formulation) is an oral TCM candidate.

  • Out of the 37 COVID-19 patients, 36 had all symptoms eliminated, save for Sensory Dysfunction & occasional cough, within the 6-day treatment period.

  • The trial that after taking RGC-COV19TM, 97.3% of the patients had their mild to moderate COVID-19 symptoms eliminated, save for Sensory Dysfunction & occasional cough, within the 6-day treatment period.

  • 15 out of the 36 patients experienced Sensory Dysfunction before receiving treatment. Among those 15 patients, 5 recovered their sensory functions, while the remaining 10 showed improvements at the end of the 6-day treatment period.

  • 31 out of 37 COVID-19 patients reported the elimination of one or more symptoms after taking 1 full dose of RGC-COV19.

  • The three non-vaccinated patients took an average of approximately 2.3 days for symptoms to be eliminated.

  • The three partially vaccinated patients took an average of approximately 3.3 days for all symptoms to be eliminated, save for Sensory Dysfunction.

  • No adverse side effects were observed, and there were no worsening of symptoms during and after consuming RGC-COV19.

  • At the end of the EARTH efficacy trial, none of the patients was hospitalized, and there was no death.

  • Price Action: RGC shares are up 5.29% at $36.80 during the market session on the last check Thursday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.